Author year | Country | Trial design | Sample | Mean age | Baseline disease | Intervention | Dosage | Duration | Outcomes | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
T | C | T | C | T | C | mg/d | /w | |||||
Adler, A. J.,1997 [20] | Canada | parallel | 11 | 11 | 45.9 | 45.4 | hyperlipidemia | GT | placebo | 900 | 12 | TG,TC,LDL,HDL |
Aslani, N.,2016 [21] | Iran | parallel | 27 | 28 | 45.3 | 39.3 | hyperlipidemia | RG | none | Â | 8 | BMI,TG,TC,LDL,HDL |
Auer 1990 [22] | Germany | parallel | 24 | 23 | NR | NR | hypertension | GT | placebo | 600 | 12 | SBP,DBP |
Byrne, DJ.,1999 [23] | UK | parallel | 20 | 11 | NR | NR | hyperlipidemia | GT | placebo | 900 | 24 | TG,TC,LDL,HDL |
Gardner, CD.,2001 [24] | USA | parallel | 16 | 18 | 50.2 | 51.6 | hyperlipidemia | GT | placebo | 999 | 12 | TG,TC,LDL,HDL |
Higashikawa, F., 2012 [25] | Japan | parallel | 28 | 26 | 52 | 51.4 | hyperlipidemia | PG | placebo | 900 | 12 | BMI,TG,TC,LDL,HDL,FBG |
Isaacsohn, JL.,1998 [26] | USA | parallel | 24 | 18 | 58 | 57.4 | hyperlipidemia | GT | placebo | 900 | 12 | BMI,TG,TC,LDL,HDL,SBP,DBP |
Jain, AK.,1993 [27] | USA | parallel | 20 | 22 | 48 | 55 | hyperlipidemia | GT | placebo | 900 | 12 | TG,TC,LDL,HDL,FBG,SBP,DBP |
Jung, ES.,2014 [28] | Korea | parallel | 28 | 27 | 50.13 | 50.83 | hyperlipidemia | AGE | placebo | Â | 12 | TG,TC,LDL,HDL |
Kannar, D.,2001 [29] | Australia | parallel | 19 | 22 | 52.6 | 57.4 | hyperlipidemia | GT | placebo | 800 | 12 | TG,TC,LDL,HDL |
Nakasone,Yasushi, 2013 [30] | Japan | parallel | 19 | 21 | 58 | 59 | hypertension | GT | placebo | 188 | 12 | SBP,DBP |
Peleg, A.,2003 [31] | Israel | parallel | 13 | 20 | 52.4 | 54.7 | hyperlipidemia | GT | placebo | Â | 16 | TG,TC,LDL,HDL |
Riad, Karin,2018 [32] | Australia | parallel | 23 | 26 | 62.8 | 61.9 | hypertension | AGE | placebo | 2400 | 12 | WC,BMI,TG,LDL,HDL,FBG,SBP,DBP |
Sangouni, Abbas A,2020 [33] | Iran | parallel | 45 | 43 | 45.2 | 44.2 | NAFLD | GT | placebo | 1600 | 12 | WC,BMI,TG,TC,LDL,HDL |
Sangouni, Abbas A,2021 [14] | Iran | parallel | 42 | 42 | 46.9 | 44.6 | MetS | GT | placebo | 1600 | 12 | TG,TC,LDL,HDL |
Sharifi, F.,2010 [34] | Iran | parallel | 20 | 20 | 47.9 | 50.5 | MetS | GT | placebo | 1800 | 6 | WC,BMI,TG,TC,HDL,FBG,SBP,DBP |
Simons, LA.,1995 [35] | Australia | crossover | 12 | 17 | 53.6 | 53.6 | hyperlipidemia | GT | placebo | 900 | 12 | TG,TC,LDL,HDL,SBP,DBP |
Superko, HR. 2000 [36] | USA | parallel | 25 | 25 | 53 | 53 | hyperlipidemia | GT | placebo | 900 | 12 | SBP,DBP |
Valls, RM.,2022 [37] | Spain | crossover | 32 | 34 | 53.7 | 52.7 | hyperlipidemia | AGE | placebo | 250 | 6 | SBP,DBP |